- published: 09 Jun 2014
- views: 14
Vernalis plc is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has two approved products; Tuzistra™ XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement with Tris Pharma Inc. to develop and commercialise multiple novel products focussed on the US prescription cough cold market, as well as several programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.
Vernalis plc is listed on the Alternative Investment Market (AIM) in London. The Group’s US commercial operations are based in Berwyn PA. The fragment- and structure-based drug discovery staff are based in Cambridge, UK and the head office is based in Winnersh, UK.
Vernalis plc - Product Pipeline Review - 2014
Vernalis ADC Film
Vernalis ADC Film -Part II.wmv
Analysis for Vernalis
Vernalis
Trio Vernalis extract05 Beethoven Triple Concerto
Vernalis wishes you a Merry Christmas!
Web Development Company Vernalis, CA - EIPDAM.com
Песня природы
Cairn Energy Plc shares set to advance another 16% says Zak Mir
I created this video with the YouTube Video Editor (http://www.youtube.com/editor)
A short film on Vernalis Consulting Assessment Development Centers
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER ...
Trio Vernalis Marie-Jeanne Sunier, violin Delphine Gosseries, cello Florence Desbiolles, piano with The Orchestre de la Ville de Bulle, dir. O. Murith L. v. Beethoven Triple Concerto 1st mvt, extract Recorded at Salle CO2, March 7th, 2009
Cairn Energy Plc (LON:CNE) shares may be set to advance another 16%, according to technical analyst Zak Mir, who dissects the oiler’s share price chart. Mir, in a Tip TV segment for Proactive Investors, highlighted that in early 2016 the share broke above the 200-day moving average and last March there was a ‘golden cross’ buy signal triggering an uptrend in the chart. “That momentum has been maintained. In the current situation you’re probably looking for the share to just make a little bit more progress,” he said. Mir says the top of the rising trend channel is as high as 280p.